Cytokinetics (CYTK) catalysts

Upcoming FDA decisions and readouts we track for Cytokinetics, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 11 Sep 2026

FreeBioList tracks 1 upcoming catalyst for Cytokinetics (CYTK, listed on Nasdaq). It concerns Aficamten (Hypertrophic cardiomyopathy (MAPLE-HCM sNDA)).

First on the list: the PDUFA date for Aficamten (Hypertrophic cardiomyopathy (MAPLE-HCM sNDA)), dated 14 Nov 2026.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.

Background reading: What a PDUFA date is, and why the FDA doesn't publish them.

Ticker: CYTK
Next catalyst: 14 Nov 2026
Type: PDUFA date
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Cytokinetics CYTK · Nasdaq	Aficamten	Hypertrophic cardiomyopathy (MAPLE-HCM sNDA)	14 Nov 2026 in 38d	PDUFA date	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states: "The Supplemental New Drug Application for MAPLE-HCM was accepted for filing by the FDA with a PDUFA date of November 14, 2026." Source: 8-K exhibit 99.1, filed 05 May 2026 · verified 11 Sep 2026

Companies working on related conditions

Tenaya Therapeutics (TNYA)MYBPC3-associated hypertrophic cardiomyopathy; PKP2-associated arrhythmogenic right ventricular cardiomyopathy

Also due in Q4 2026

BridgeBio Pharma (BBIO)PDUFA date for BBP-418, 27 Nov 2026
Merck & Co. (MRK)PDUFA date for Ifinatamab deruxtecan (I-DXd), 10 Oct 2026
Zai Lab Ltd. (ZLAB)PDUFA date for Povetacicept, 30 Nov 2026
Capricor Therapeutics (CAPR)PDUFA date (extended) for Deramiocel, 22 Nov 2026
Vanda Pharmaceuticals (VNDA)PDUFA date for Quimilza (imsidolimab), 12 Dec 2026
Ionis Pharmaceuticals (IONS)PDUFA date for Bepirovirsen, 26 Oct 2026